A Registry Study on HIV-related Lymphoma
Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
1 other identifier
observational
300
4 countries
6
Brief Summary
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2021
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 25, 2021
CompletedFirst Submitted
Initial submission to the registry
January 5, 2022
CompletedFirst Posted
Study publicly available on registry
February 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2029
ExpectedApril 6, 2023
April 1, 2023
3 years
January 5, 2022
April 4, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
2-year overall survival (OS)
OS measured from the date of diagnosis to last follow-up or to death from any cause.
2 years
2-year progression-free survival (PFS)
PFS calculated from the date of diagnosis to the time of progression, relapse, or death.
2 years
Secondary Outcomes (4)
Incidence of relapse (IR)
5 years
Non-relapse mortality (NRM)
5 years
5-year overall survival (OS)
5 years
5-year progression-free survival (PFS)
5 years
Eligibility Criteria
Unselected cohort of adults with HIV-lymphoma
You may qualify if:
- Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
- HIV-infection at time of lymphoma diagnosis
- Lymphoma diagnosis since 01.01.2010
- Adult patients ≥ 18 years
- Written informed consent
You may not qualify if:
- HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma
- Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Red Cross Hospital Munich
Munich, Select One Option, 80634, Germany
University Hospital Cologne
Cologne, 50937, Germany
Amsterdam University Medical Centers
Amsterdam, Netherlands
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
University Hospital of Wales
Cardiff, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Marcus Hentrich, MD
Rotkreuzklinikum München
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 6 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Department of Hematology and Oncology
Study Record Dates
First Submitted
January 5, 2022
First Posted
February 9, 2022
Study Start
August 25, 2021
Primary Completion
August 31, 2024
Study Completion (Estimated)
August 31, 2029
Last Updated
April 6, 2023
Record last verified: 2023-04